ABCB1 Gene Polymorphisms are Associated with Adverse Reactions in Fluoropyrimidine-Treated Colorectal Cancer Patients

• DOI: 10.2217/pgs.10.159
• Publication Date: 2010-12-13T16:07:36Z
• Authors: Eva Gonzalez-Haba; Maria I García; Lucia Cortejoso; Carolina López-Lillo; Nélida Barrueco; Pilar García-Alfonso; Sonsoles Alvarez; Jose L Jiménez; María L Martín; Maria A Muñóz-Fer...; María Sanjurjo; Luis A López-Fern...
• Keywords: Male; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; Genotype; DNA; Middle Aged; Deoxycytidine; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Humans; Female; ATP Binding Cassette Transporter, Subfamily B, Member 1; Fluorouracil; Colorectal Neoplasms; Capecitabine; Aged; Retrospective Studies

To find out whether SNPs in the transporter gene ATP-binding casette B1 (ABCB1) were related to adverse effects colorectal cancer patients treated with 5-fluorouracil (5-FU) or capecitabine.Patients a 5-FU-based therapy (n = 67) capecitabine-based 74) recruited and genotyped for ABCB1 rs1128503 (C1236T), rs2032592 (G2677T/A) rs1045642 (C3435T). Clinical data reactions recorded. genotypes of statistically analyzed association most frequent reactions.Statistical associations observed, suggesting lower risk neutropenia (p 0.013) hand-foot syndrome (HFS; p 0.027) carriers T variation capecitabine-treated patients, capecitabine had HFS 0.033), while those 5-FU higher diarrhea 0.035), at less developing 0.033).This is first time evidence has been found differing pharmacogenetic markers treatments. Genotyping prior chemotherapy administration could help reduce patients.